Saracatinib

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massachusetts General Hospital), as well as BOS expert Steven Hays, MD (UCSF Health) to discuss the current treatment landscape and unmet need for PH-ILD and BOS as well as the role for LAM-001 as a potential new therapeutic option. To register, click here . The event will provide an overview of LAM-001, the Company's proprietary investigational once-daily inhaled DPI formulation of rapamycin (mTOR inhibitor), currently in Phase 2 clinical trials for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS). The KOLs will discuss mTOR inhibition as a potentially disease modifying mechanism of action across these conditions, focusing on its potential role in suppressing pulmonary smooth muscle hyperproliferation, limiting fibroblast driven vascular and interstitial remodeling, and modulating inflammatory signaling, along with the unique potential advantages of delivering therapy through an inhaled route. The KOLs will review current treatment options as well as the emerging treatment landscape for each condition. Data from the recently presented Phase 2a trial of LAM-001 in pulmonary hypertension will be reviewed as well as the design and objectives of the ongoing Phase 2 BOS and Phase 2b PH-ILD studies. A live question and answer session will follow the formal presentations. About Aaron B. Waxman, MD, PhD Aaron B. Waxman, MD, PhD, is Director of the Pulmonary Vascular Disease Program at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. Dr. Waxman's clinical practice and research programs center on pulmonary arterial hypertension (PAH), right heart failure, thromboembolic disease, and the broader spectrum of pulmonary vascular disease. Across local and national efforts, Dr. Waxman has served as Principal Investigator on more than 15 clinical trials in pulmonary hypertension. These include the Phase 2 SPECTRA trial of sotatercept, which helped establish activin signaling inhibition as a novel therapeutic pathway in PAH, and the INCREASE trial of inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease—a study that defined a new treatment standard for a previously underserved patient population. He has authored more than 180 peer-reviewed publications, and his research has been supported by the National Institutes of Health, including the National Heart, Lung, and Blood Institute. About Paul Yu, MD, PhD Paul Yu, MD, PhD is Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, where he holds the Charles and Elizabeth Sanders Endowed Chair. A physician-scientist trained in immunology and cardiovascular medicine, Dr. Yu's research focuses on bone morphogenetic protein and transforming growth factor-beta signaling in cardiovascular homeostasis, repair, and disease. His work spans pulmonary vascular disease, cardiovascular rheumatology, and rare disorders such as fibrodysplasia ossificans progressiva. Dr. Yu has translated several scientific discoveries into therapeutics, including contributions to sotatercept for pulmonary arterial hypertension and the clinical repositioning of saracatinib for fibrodysplasia ossificans progressiva. He has published over 120 peer-reviewed studies and has been elected to the American Society for Clinical Investigation. About Steven Hays, MD Steven Hays, MD, is Medical Director of the UCSF Advanced Lung Disease and Lung Transplant Program and Professor of Medicine at the University of California, San Francisco. Under his leadership, the program has grown to be one of the nation's largest transplant centers while consistently achieving superior outcomes, receiving INTERLINK's Chairman's Award for Transplant Excellence for three consecutive years. Dr. Hays brings deep clinical expertise across the full spectrum of advanced lung disease, including cystic fibrosis, alpha-1 antitrypsin deficiency, interstitial lung disease, and emphysema. A dedicated clinical investigator, Dr. Hays has served as principal investigator on NIH-funded, industry-sponsored, and investigator-initiated trials. His research portfolio spans lung transplant immunology, chronic lung allograft dysfunction, infectious disease, and transplant digital health. He has authored more than 110 peer-reviewed publications and has been an invited speaker at the American Thoracic Society, the International Society of Heart and Lung Transplantation, and the American Society of Transplantation, among others. He is a Fellow of the American College of Chest Physicians, and a member of the American Thoracic Society and the International Society of Heart and Lung Transplantation, where he serves on the Pulmonary and Infectious Disease Councils. He is a recipient of the American Thoracic Society's Outstanding Clinician Award (California Chapter) and a member of the prestigious UCSF Council of Master Clinicians. About LAM-001 LAM-001 is a proprietary, investigational, once-daily inhaled formulation of rapamycin, also known as sirolimus. LAM-001’s potential as a disease-modifying agent in PH stems from its ability to inhibit mTOR-mediated pulmonary arterial smooth muscle cell proliferation, to limit endothelial cell dysfunction, and to suppress inflammatory signaling, leading to improvement in pulmonary vascular remodeling. The mTOR pathway has been shown to be activated in pulmonary arteries of patients with PH, and mTOR inhibition with rapamycin has been shown to reverse smooth muscle cell hyperproliferation and to attenuate pulmonary vascular remodeling and cardiopulmonary dysfunction in multiple published nonclinical models. Additionally, in published non-clinical studies, hyperactive mTOR signaling has been shown to promote fibroblast activation, myofibroblast differentiation, and extracellular matrix deposition in injured or inflamed lung tissue, and mTOR inhibition has been shown to exert direct antifibrotic activity, suppressing profibrotic cytokine signaling, reducing collagen accumulation, and attenuating parenchymal fibrosis. These effects are particularly relevant in PH-ILD, where vascular remodeling and progressive fibrosis evolve in parallel and amplify pulmonary vascular load. LAM-001 is designed to enhance pulmonary delivery and to reduce systemic exposure of rapamycin, offering a promising, potentially disease-modifying, therapy for multiple pulmonary diseases. LAM-001 is currently being studied in multiple indications including PH-ILD, a serious and progressive condition affecting an estimated 200,000 patients between the U.S. and Europe. Based on compelling Phase 2a data presented at the American Thoracic Society (ATS) in May 2026, the company has advanced LAM-001 into a Phase 2b PH-ILD trial and data is anticipated in the first quarter of 2028. LAM-001 is also being evaluated in a Phase 2 study in bronchiolitis obliterans syndrome post lung transplant (BOS), a serious complication with an estimated prevalence of ~30K patients between the U.S. and Europe by 2032. The trial is fully enrolled, and data is anticipated in the first quarter of 2027. In late 2026, the company also plans to initiate a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a severe complication of pulmonary sarcoidosis with no approved therapy, that affects an estimated ~60K patients in the U.S. and Europe. About Quince Therapeutics, Inc. Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide. Forward-Looking Statements Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” “designed,” “aims,” or other similar words. Examples of forward-looking statements include, among others, statements relating to the design and potential benefits of LAM-001, including as a disease-modifying therapy for pulmonary disease; anticipated regulatory and development processes and timelines, including the expected timing to initiate the planned Phase 2 trial of LAM-001 in SAPH, the expected timing for data readouts from the ongoing Phase 2 trial of LAM-001 in BOS and the ongoing Phase 2b trial of LAM-001 in PH-ILD; the Phase 2a data of LAM-001 in PAH and PH-ILD supporting continued development of LAM-001 in PH-ILD and the potential benefit across exercise capacity, pulmonary hemodynamics, cardiac stress and lung function; observed improvements in 6MWD and PVR in the Phase 2a trial potentially suggesting broader effects on cardiopulmonary physiology; the estimated patient populations in the U.S. and Europe for PH-ILD, BOS and SAPH; and the potential advantages of mTOR inhibitors in PH-ILD, BOS and SAPH. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to LAM-001; the ability to obtain and maintain regulatory approval; competition in the company’s industry; the scope, progress and expansion of developing LAM-001; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; the company’s ability to attract or retain key management, members of the board of directors and other personnel; the company’s ability to fund its operations and clinical development plans, including its anticipated cash runway; the impacts of general macroeconomic and geopolitical conditions on the company’s business and financial position; and other risks and uncertainties described in the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on August 14, 2026 and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law. Contacts Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com

摘要 单细胞与空间组学技术为解析疾病机制带来前所未有的机遇，但该过程需要专家团队反复试错，并跨多种模态开展推理。本文提出对话式系统LungChat，用于整合多组学分析与生物医学发现。系统采用层级化多智能体架构：由监督智能体将自然语言问题拆解为并行、依托工具执行的任务，覆盖单细胞与空间组学分析、文献与临床试验信息整合、药物重定位。为预测新型治疗手段，LungChat实现方向感知重定位与靶点挖掘算法DART，可在细胞类型层面区分能够逆转疾病转录程序、以及会加重疾病表型的扰动，以此实现安全性预测。 受控的架构消融实验表明：层级任务调度可以提升模型「自知无法回答则拒绝输出」的能力、降低token消耗，并且在复杂多步骤任务上维持优异性能。 在肺部疾病案例研究中，LungChat通过药物关联筛选，独立将萨拉卡替尼（saracatinib）列为特发性肺纤维化（IPF）候选药物，后续再经由DART开展细胞层面分析；该化合物已经进入STOP‑IPF临床试验（NCT04598919）。系统还通过完整调度分析，筛选出已经成熟用于慢性阻塞性肺疾病（COPD）的治疗药物丙酸氟替卡松。 本系统不局限于单一组织，为构建可核验的智能体AI系统提供范式，支撑可复现的科学发现。 https://chat.lungmap.net pankaj.rajdeo@cchmc.org bruce.aronow@cchmc.org nathan.salomonis@cchmc.org #对话式多智能体#整合多组学#单细胞组学#空间组学#药物重定位#生物医学发现#工具增强大模型#可复现分析 结果 跨多组学与生物医学知识的协同多智能体分析 图1  LungChat系统架构与工作流 集成对话式AI与多组学分析的层级化多智能体系统。监督智能体调度4个专业化子智能体（单细胞、空间组学、研究、图谱智能体）；子智能体访问整理好的数据仓库（单细胞RNA‑seq、空间转录组、药物化合物、调控网络、文献），产出可直接用于论文发表的可视化图表、可供检验的科学假说、治疗靶点预测、可复现分析工作流。系统支持迭代式科学工作流（定义问题→探索数据→整合证据→生成假说→测试优化），具备长期记忆与MCP可扩展基础设施，用于适配新增工具。 基准测试与架构消融实验 图2  5大赛道架构消融评测 共计1,080次评估 (a) 4种消融配置下单步查询任务性能（50查询×3重复×4模式，合计600次评估）； (b) 3个评测赛道下每条查询平均token消耗量，数值越低越好； (c) 安全评测「自知不能回答就拒绝输出」指标（17查询×3重复×4模式，合计204次评估），多智能体配置拦截非法工具调用率提升35.3个百分点； (d) 多工具调度、拆解压力测试结果（20查询×3重复×2模式，合计120次评估），证明复杂任务上不同架构性能相当。 细胞类型分辨的治疗优先级排序与机制探究 图3  肺纤维化的治疗靶点与药物自动优先级排序 (a) LungChat并行多智能体编排，由监督智能体完成任务分派。 (b) 可复现工作流的规划与任务拆解。 (c) 肺纤维化肺泡成纤维细胞中上调、下调基因的排序。 (d) 利用ToppGene做基因集富集分析，识别肺纤维化中已知的可药物作用通路。 (e) 纤维化标志物的空间转录组定位。 (f) 依据细胞类型空间邻近度对受体‑配体相互作用进行排序，对比肺纤维化组与对照组（Xenium平台）的细胞‑细胞通讯强度。 (g) 结合DART细胞类型安全性分析开展药物重定位：萨拉卡替尼被识别为最优候选药物；脱靶监测识别出杯状细胞与神经内分泌细胞。 图4  解析新型疗法的调控机制与细胞作用靶点 (a) 任务规划与拆解，明确LPAR1抑制剂在肺纤维化中的多种作用机制。 (b) 在iLINCS数据库中筛选具备体外基因表达应答数据的LPAR1抑制剂。 (c) Xenium与Visium‑HD平台下LPAR1的空间分布对比（同张组织切片，由空间组学智能体完成分析）。 (d) LPAR1在成人健康肺细胞群中的表达水平与细胞占比（HLCA数据库，单细胞智能体完成分析）。 (e) DART预测受影响最显著的肺部疾病、检测技术以及发育相关扰动（组学数据仓库）；给出体外LPAR激动剂处理（iLINCS）条件下，上述扰动被逆转或是进一步加剧的预测结果。 (f) 基于已注释转录因子（TF）靶点与通路相互作用（NetPerspective）推导得到的基因调控网络；高亮标注关键转录因子节点以及经ToppGene注释的TGF‑β信号响应基因。 调控机制评估 表1  LungChat的数据资源与系统覆盖范围 数据 人肺细胞图谱第2版（Human Lung Cell Atlas v2）数据集存放于CELLxGENE，检索号 6f6d381a‑7701‑4781‑935c‑db10d30de293 胎儿肺细胞图谱数据集存放于CELLxGENE，检索号 2d2e2acd‑dade‑489f‑a2da‑6c11aa654028 LungMAP联盟的其他数据集检索号 LMEX0000004400、LMEX0000004401 空间转录组数据存放于基因表达综合数据库Gene Expression Omnibus，GEO检索号GSE276945，包含子样本GSM8505452 详细总结 思维导图 论文基础信息 5大智能体分工 DART：方向感知药物重定位与靶点算法 本文核心新方法 系统消融实验 多智能体vs扁平单智能体 案例1：特发性肺纤维化IPF 肺纤维化 案例2：慢性阻塞性肺病COPD 与同类生物对话Agent横向对比 参考 A Conversational Multi-Agent AI System for Integrated Multi-Omics Analysis and Biomedical Discovery https://www.biorxiv.org/content/10.64898/2026.08.08.743577v1 注：AI辅助创作，如有不当欢迎指出。内容仅供参考，不构成任何建议。 End